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ABSTRACT
Recent studies suggest that gastrointestinal tract microbiota modulate 
cancer development in distant non-intestinal tissues. Here we tested mechanistic 
hypotheses using a targeted pathogenic gut microbial infection animal model with a 
predilection to breast cancer. FVB-Tg(C3-1-TAg)cJeg/JegJ female mice were infected 
by gastric gavage with Helicobacter hepaticus at three-months-of-age putting them 
at increased risk for mammary tumor development. Tumorigenesis was multifocal 
and characterized by extensive infiltrates of myeloperoxidase-positive neutrophils 
otherwise implicated in cancer progression in humans and animal models. To test 
whether neutrophils were important in etiopathogenesis in this bacteria-triggered 
model system, we next systemically depleted mice of neutrophils using thrice weekly 
intraperitoneal injections with anti-Ly-6G antibody. We found that antibody depletion 
entirely inhibited tumor development in this H. hepaticus-infected model. These data 
demonstrate that host neutrophil-associated immune responses to intestinal tract 
microbes significantly impact cancer progression in distal tissues such as mammary 
glands, and identify gut microbes as novel targets for extra-intestinal cancer therapy.
INTRODUCTION
Breast cancer is a leading cause of neoplasia-
associated mortality [1]. While studying intestinal cancer 
in mouse models, we observed that targeted orogastric 
infection with Helicobacter hepaticus, a murine 
bacterium frequently colonizing the gut of mice [2–4], 
causes mammary neoplasia with particularly increased 
frequency [5]. We hypothesized that unbalanced host 
immune responses to enteric bacteria may promote the 
development of cancer in epithelia distant from the gut [6]. 
Since that time, genetically-engineered and diet-associated 
mouse models of cancer, wound healing, and obesity have 
provided evidence to support our original hypothesis that 
gut bacteria have consequences in systemic immunity 
[7–9].
Several lines of evidence support the roles of GI tract 
microbial flora in promoting intestinal neoplasmatogenesis 
[3, 5, 10–14]. However, linking gut bacteria with systemic 
innate immune-related effects that enhance tumor 
formation throughout the body expands this paradigm [5, 
6]. This notion is challenging, especially in the light of 
recent reports demonstrating that gut microbe dysbiosis 
undermines the outcome of both immune and non-immune 
chemotherapeutic cancer treatment modalities [15, 16]. 
In order to identify the key immune cell players, prior 
studies have used combinations of immunohistochemistry, 
targeted immune depletions, and adoptive cell transfers 
[5, 17–19]. In those studies, reciprocal relationships 
exist between innate immune neutrophils [11] and anti-
inflammatory Interleukin (IL)-10 -dependent activities 
of CD4+ T regulatory (Treg) lymphocytes that bestow 
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immune homeostasis [5, 10, 20]. Indeed, neutrophils 
have been identified as important contributors of cancer 
initiation and development [21]. Through the generation 
of reactive oxygen species (ROS), neutrophils induce 
genotoxic damage, thus contributing to the mutagenic 
events in the initial steps of carcinogenesis [22–24]. Also, 
cytokines and chemokines as well as serine proteases 
secreted by tumor-associated neutrophils shape the tumor 
microenvironment and promote tumor growth [25, 26].
In the present study, we used female genetically-
engineered FVB-Tg(C3-1-TAg)cJeg/JegJ mice with 
a predilection to develop mammary cancer [27]. In 
this model system, the C3(1)/SV40 T antigen is over-
expressed after exposure to sex steroid hormones 
during development of prostate and mammary cancer 
[28, 29]. This mouse model recapitulates all stages of 
human mammary carcinomas. These lesions have been 
previously classified as infiltrating ductal carcinomas, 
including ductal epithelial cell atypia and mammary 
intraepithelial neoplasia (MIN), which corresponds to 
the human ductal carcinoma in situ [29]. Here we record 
that targeted orogastric infection with H. hepaticus 
increases mammary tumor multiplicity recapitulating 
the classical C3-1-TAg mouse mammary tumorigenesis 
pattern. Further, systemic depletion of neutrophils, 
a key innate immune inflammatory cell, can block 
this extra-intestinal tumorigenic phenomenon. These 
data demonstrate that host inflammatory responses to 
environmental microbes significantly impact cancer 
progression in distant non-intestinal tissues by a 
neutrophil -mediated mechanism.
RESULTS
Orogastric gavage with Helicobacter hepaticus 
increases mammary tumor burden in 
genetically-prone C3-1-TAg mice
It was previously shown that infection with 
enteropathogenic H. hepaticus rapidly induced mammary 
tumor formation in genetically-susceptible ApcMin/+ 
[ApcMin] mice [5, 6, 30, 31]. However, the use of 
ApcMin mice as a model of mammary cancer has certain 
peculiarities, raising doubts about broader relevancy 
of roles of gut microbiota in mammary epithelial 
carcinogenesis. To examine this evident gut microbe-
mammary linkage further, we first tested orogastric 
challenge with H. hepaticus in the FVB-Tg(C3-1-TAg)
cJeg/JegJ mouse model [29]. Within three weeks of 
infection, we found numerous small palpable tumors 
arising in multiple mammary tissue sites of three-
month-old C3-1-TAg mice infected with H. hepaticus 
(Figure 1A). By comparison, sham media-dosed matched 
control animals had significantly fewer palpable tumors 
(Figure 1B).
The unencapsulated expansile tumors in both H. 
hepaticus- and sham-treated mice had the typical C3-1-
TAg mouse mammary adenocarcinoma histomorphology 
(Figures 2A–2C). In the non-tumoral mammary tissue, ducts 
and terminal duct lobular units (TDLU) showed a spectrum 
of hyperplastic, preneoplastic, and early neoplastic lesions 
depicting the well-characterized stages of the C3-1-TAg 
mouse mammary tumorigenesis progression (Figure 2D). 
Figure 1: Tumor multiplicity assessment in experimental groups of 15-week-old C3-1-TAg mice. (A) Grossly visible 
tumors (arrow) found in each mouse were removed, placed on a petri dish and counted. (B) The statistical analysis of mammary tumor count 
data shows that infection with H. hepaticus accelerates tumorigenesis, whereas the depletion of neutrophils negates this effect. The y-axis 
depicts the mean ± SEM of mammary tumor counts. *p < 0.05. The points correspond to the mean of total tumors counted in each mouse.
Oncotarget9389www.impactjournals.com/oncotarget
In the non-tumoral areas the affected mammary epithelia 
of H. hepaticus-treated mice appeared to be in more 
advanced tumorigenesis stages by comparison with the 
uninfected controls. In order to confirm this observation 
we determined histomorphometrically the percentage of 
abnormal glands at each one of four critical histological 
stages of mammary tumorigenesis in H. hepaticus-infected 
and non-infected mice. We found that the classification 
of abnormal glands according to their histological stage 
differed significantly between experimental groups 
(P = 0.0307), with H. hepaticus-infected mice having a 
higher percentage of abnormal glands with mammary 
intraepithelial neoplasia (MIN) when compared to controls 
(Figure 2E).
Gut microbial challenge leads to up-regulation of 
inflammatory cells in mammary tissue
Knowing that inflammatory cells and factors were 
pivotal in etiopathogenesis of microbe-induced mammary 
[5, 17, 32] and prostate [18] tumors, we next examined 
whether inflammatory cells were increased in C3-1-TAg 
mice undergoing infection with H. hepaticus. We found the 
tumor-associated inflammatory cell component residing at 
the periphery of well-defined tumors (Figure 3A) consisted 
of abundant macrophages, neutrophils, myeloid precursor 
cells with ring-shaped nuclei [33, 34], mononuclear cells, 
and mast cells. The same types of inflammatory cells were 
found in the connective tissue stroma within the tumor, 
Figure 2: Effects of H. hepaticus on mammary gland carcinogenesis. Tumors of both H. hepaticus-infected and uninfected 
control C3-1-TAg mice shared similar histomorphological patterns. (A) Neoplastic cells arranged in solid sheets, cords or nests with 
minimal gland formation and small amounts of intervening stroma. (B) Glandular-like growth was seen in occasional areas at the periphery 
of the tumors. Note irregular glands in moderate to large amounts of desmoplastic stroma. (C) Large solid cord arrangement of neoplastic 
cells with variably sized areas of either diffuse or commedo type intratumoral necrosis. (D) The initial stages of mammary tumorigenesis. 
From left to the right there is progressively increased epithelial pseudostratification, cellular atypia, nuclear pleomorphism and mitotic 
figures. (E) Classification of abnormal glands in non-tumoral areas according to their histological stage. The mammary glands of H. 
hepaticus-infected mice are in more advanced stages of neoplastic progression compared to those of uninfected controls. Hematoxylin and 
Eosin (A, B, C and D); Scale bars: 250 μm (A, B and C) and 25 μm (D).
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with the exception of mast cells, which were sparse. Mast 
cells as well as neutrophils, however, were topographically 
associated with early neoplastic lesions such as MIN in the 
non-tumoral areas of the mammary glands.
Comparing histomorphologically similar MIN 
lesions in the two experimental groups, we noticed 
that neutrophils accumulated in higher numbers 
around the MIN lesions when mice were infected with 
H. hepaticus. Tumor associated neutrophils (TAN) were 
previously shown to enhance tumorigenesis in mouse 
models [35]. To quantify this result we performed 
counts of myeloperoxidase (MPO)-positive cells 
(neutrophils) in histologically comparable MIN lesions 
of both H. hepaticus-infected and uninfected mice. We 
found that the H. hepaticus infection status correlated 
with higher numbers of MIN-associated MPO-positive 
cells in statistically significant levels (P = 0.002) 
(Figure 3B).
Systemic depletion of neutrophils inhibits 
mammary tumor formation
Finally, based upon earlier findings showing that 
neutrophils are a consistent feature of H. hepaticus-
induced inflammation [36] and cancer [10, 11, 20], and 
due to the emerging role of neutrophils in carcinogenesis 
[21, 37, 38], we tested whether Ly-6G+ neutrophils were 
required for mammary cancer in this mouse model. To 
test this we used thrice-weekly intraperitoneal injections 
with anti-Ly6G clone 18A previously shown to target 
mature neutrophils in mice [39]. While H. hepaticus-
infected mice had multifocal well-sized mammary 
adenocarcinoma tumors (8/9, 88%), H. hepaticus-infected 
mice that were treated with anti-Ly6G antibody had no 
evidence of mammary adenocarcinoma tumors (0/9, 
0%) (Figure 1B). The neutrophil depleted mice had 
only preneoplastic and early neoplastic lesions in their 
Figure 3: H. hepaticus infection up-regulates MIN-associated neutrophils. (A) The tumor-associated inflammation was 
comparable in large-sized neoplasms of both H. hepaticus-infected and uninfected control mice. Neutrophils (black arrow-heads), 
myeloid precursor cells (white arrow-head), mast cells (black arrow) and macrophages (white arrow) at the periphery of tumors are 
shown. (B) Morphometric counts of MPO-positive cells (arrows) in MIN lesions. The numbers of neutrophils are significantly higher 
in H-hepaticus infected mice compared to controls. Hematoxylin and Eosin (A) IHC; Diaminobenzidine chromogen, Hematoxylin 
counterstain (B) Scale bars: 25 μm (A) and 50 μm (B) Numbers on the y-axis of bar graph correspond to the mean ± SEM of MPO+cells. 
***p < 0.0001.
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mammary gland epithelia (Figure 4). Specifically, the most 
advanced histopathological lesion found [7] was low and 
high grade MIN (carcinoma in situ) in three mice (3/9, 
33%), hyperplasia with marked atypia in two (2/9, 22%), 
hyperplasia with atypia, intermediate grade in one (1/9, 
0.09%) hyperplasia without atypia, low grade in three 
mice (3/9, 33%).
DISCUSSION
In the present study we use the well-characterized 
C3-1-TAg mouse model of mammary cancer to show that 
bacteria residing in the gut mucosa affect the evolution 
of neoplastic lesions in mammary glands. We find here 
that the neutrophil is an important cellular element of this 
mechanism, which links innate immune and neoplastic 
events occurring in topographically distant epithelia. This 
highlights the neutrophil as an important mediator of the 
remote effect of gut microbiota on mammary epithelial 
carcinogenesis. Further, these findings build upon the 
pivotal role of systemic immune balance in emerging 
pre-neoplastic lesions throughout the body not obviously 
linked with chronic inflammation.
Previously we have shown that H. hepaticus-
infected C57BL/6 ApcMin Rag2-deficient female mice 
develop mammary tumors with increased frequency [5]. 
This was the first study providing compelling experimental 
evidence linking the effects of gastrointestinal bacteria 
with mammary carcinogenesis. Further, this provided 
evidence that innate immunity alone was sufficient 
for distant carcinogenesis triggered by gut bacterial 
infection. Subsequently we showed that male ApcMin 
mice infected with H. hepaticus develop prostate tumors 
transplantable to uninfected mice using purified lymph 
node cells obtained from H. hepaticus-infected mice 
alone [18], implicating systemic innate immune cell 
trafficking in distant carcinogenic events. Indeed, the 
abundance of morphologically-distinctive myeloid cells 
throughout target tissues in the ApcMin model supports 
the notion of gut bacteria-triggered systemic trafficking 
of immune precursor cells [18]. However, the use of 
ApcMin mice as a model of mammary or prostate 
carcinogenesis raises some questions. These mice 
exhibit a predilection for intestinal polypoid adenomas, 
due to their heterogygous adenomatosis polyposis coli 
gene status [30] and accelerated thymic involution 
[40]. Given microbe-dependent intestinal polyposis in 
this model [5, 41], it is difficult to assess whether the 
mammary cancer is due to H. hepaticus infection per se 
or to microbe-increased multiplicity of intestinal polyps. 
Taken together, these facts raise doubts about roles of gut 
microbiota in mammary epithelial carcinogenesis beyond 
ApcMin mice. The results of the present paper contribute 
towards showing that H. hepaticus accelerates mammary 
carcinogenesis in other animal systems, in this case the 
C3-1-TAg female mouse that is a widely utilized mouse 
model for hormonally-dependent cancer [28]. Thus the 
present findings build upon our previous observations 
and expand upon the ApcMin mouse mammary cancer 
paradigm.
Further, these data provide additional evidence that 
breast cancer is associated with microbial dysbiosis in 
the gut. Altering gut microbes can regulate the immune 
system and lower the risk of breast cancer; in particular, 
overgrowth or lack of certain types of bacteria in the 
gut have been associated with many diseases ranging 
from obesity, to digestive disorders, to cancers [42]. 
Differences in the bacterial populations in breast tumor 
Figure 4: The depletion of neutrophils with anti-Ly-6G antibody blocks effect of H. hepaticus-promoted C3-1-TAg 
mouse mammary carcinogenesis. Fifteen-weeks-old H. hepaticus-infected C3-1-TAg mice had the typical for this mouse model 
mammary tumors. At the same timepoint their anti-Ly6G-treated counterparts had early neoplastic changes but no tumors at all. Hematoxylin 
and Eosin. Scale bars: 250 μm
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tissue and healthy breast tissue have been reported 
[43]. Frequent use of antibiotics that may disrupt the 
microbiome is associated with breast cancer development 
and relapse [44–46]. Interestingly, immune dysregulation 
can be transferred in mice by fecal microbe transplant 
[47–50]. Additionally, the microbiome plays a key role 
in estrogen cycling in the body, and gut dysbiosis results 
in higher circulating estrogens which has been linked 
to postmenopausal breast cancer [51–54]. Estrogen and 
neutrophil dysregulation are hallmarks of breast cancer 
development [55], and a high neutrophil to lymphocyte 
ratio is associated with breast cancer relapse in patients. 
Both these cell populations are clearly modulated by the 
microbiome and inflammation [56–59].
Interestingly, our current results suggest that 
the remote effect of gut microbiota in mammary 
carcinogenesis does not specifically depend on the 
molecular pathway of mammary carcinogenesis 
involved. C3-1-TAg mice develop mammary cancer 
due to hormonally-dependent functional inactivation 
of the P53 and Rb tumor suppressor genes, which leads 
mammary epithelia to cell cycle regulation defects, 
uncontrolled proliferation and resistance to apoptosis 
[29]. The inactivation of these tumor suppressors and the 
dysregulation of the cell growth and apoptosis pathways 
they control are common in human breast cancer 
[29, 60]. Although the role of the APC gene, which is 
central in the β-catenin/WNT pathway of carcinogenesis 
in human breast cancer is emerging [61], neither APC 
mutant mice nor humans carrying germline mutations 
in APC develop spontaneously mammary cancer in a 
high percentage [62, 63]. By contrast C3-1-TAg mice 
inevitably develop mammary neoplasms [29]. This fact 
presumably reflects the more universal role of the P53 
and Rb genes in the various types of neoplastic disease 
compared to the APC gene.
Our compiled results also show that the effect of 
intestinal H. hepaticus on mammary carcinogenesis does 
not connect specifically with the histological type of 
the mammary tumor. Previously we found H. hepaticus 
promotes formation of mammary adenosquamous 
carcinoma in ApcMin mice [5]. Here, we find in the 
C3-1-TAg mouse that it accelerates the growth of solid 
carcinomas, resembling infiltrating ductal carcinomas of 
humans [29, 64, 65].
Importantly, the C3-1-TAg mice on a FVB 
background develop neither IBD nor intestinal tumors 
[29]. This suggests that subclinical, rather than overt, 
alterations in the immune status are sufficient for the 
induction of phenotypically distinct effects on mammary 
carcinogenesis. Other proliferative and neoplastic 
pathologies reported to arise in different anatomical sites 
of female C3-1-TAg mice, such as the sweat glands of 
the foot pads, the salivary glands, and the vomeronasal 
organ [29] were not observed in the present study. This 
lack of tumors in other sites was predictable since these 
pathologies occur in older animals more than five-months-
of-age, a time point that was not reached with young (less 
than four-months-of-age) mice in our present study. Unlike 
ApcMin, the C3-1-TAg mice are immunocompetent, 
which suggests that immune system defects are not 
necessary for the remote effect of GI tract bacteria on 
mammary carcinogenesis. Although T regulatory (Treg) 
cells function reciprocally with neutrophils [36], the roles 
for Treg cells in preventing mammary neoplasia were not 
specifically examined in this study. Knowing that C3-1-
TAg mice exhibit hormone-dependent carcinogenesis [29], 
and that neutrophils robustly interact with estrogen and 
IL-10 [66], the relationships between microbes, hormones, 
immunity and cancer are a key topic for future studies.
It appears that H. hepaticus is not unique among gut 
bacteria exerting effects on mammary gland tissue. Our 
other recent findings show that the probiotic bacterium 
Lactobacillus reuteri, when introduced in the GI tract 
flora of mice, has the opposite effect of suppressing 
mammary tumor formation in genetically-susceptible 
HER2 mutant mice [7]. In both cases involving gut 
microbiota, whether the acceleration of mammary 
carcinogenesis by pathogenic H. hepaticus or suppression 
of mammary tumorigenesis by probiotic L. reuteri, we 
discover differences in the immune cell composition of the 
mammary gland microenvironment. An interesting aspect 
is that these gut-mammary connections may be covert; 
even in the absence of demonstrable inflammatory disease 
in the gut or elsewhere, we find that H. hepaticus-infected 
mice have not only higher risk for cancer but also more 
frequent inflammatory cells associating with mammary 
glands at early neoplastic stages.
In the present study we found that neutrophils 
associate with mammary lesions in higher numbers in 
the H. hepaticus-infected mice when compared to their 
uninfected controls. Neutrophils are a consistent feature 
of H. hepaticus-induced inflammation [36] and cancer 
[10, 11, 20]. Other evidence for the role of neutrophils in 
carcinogenesis and tumor evolution is emerging and the 
therapeutic approach of targeting the tumor-associated 
neutrophils has been recently introduced [21]. Studies 
in samples from many different types of human tumors 
suggest that a high neutrophil to lymphocyte ratios 
predicts a poor clinical outcome [38]. Also, the depletion 
of neutrophils has been shown to block cancer evolution 
in mouse models of fibrosarcoma [67], pancreatic islet cell 
[68], colonic [11], and pulmonary carcinoma [35].
Taken together with our earlier data these facts 
led us to test whether the depletion of neutrophils could 
affect mammary carcinogenesis in this mouse model, as 
well. Recognizing the etiopathogenic potential of myeloid 
immune precursor trafficking in lymph nodes, spleen, and 
target tissues after H. hepaticus infection [18], it’s possible 
that depleting Ly-6G+ cells includes other relevant 
immune cells; although, clone 1A8 was previously shown 
to be specific for mature neutrophils [39]. We found that 
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the H. hepaticus-infected C3-1-TAg mice depleted of 
Ly-6G+ neutrophils had significantly fewer mammary 
lesions, and in those cases only preneoplastic and early 
neoplastic lesions, in contrast to their non-depleted 
matching controls which exhibited palpable mammary 
tumors. The dependence of mammary tumorigenesis upon 
the presence of neutrophils highlights the neutrophil as an 
important mediator of the remote effect of gut microbiota 
on mammary epithelial carcinogenesis. Adoptive transfer 
experiments [18] using highly purified gut bacteria-
stimulated myeloid and neutrophil cell populations will 
address this in future studies.
In conclusion, the results of the present study 
indicate that gut microbiota bacterial elements, in the 
absence of overt inflammatory disease, contribute to the 
character of the subclinical, systemic inflammatory tone 
of the mammalian organism. Based on these findings 
it appears that systemic inflammatory tone, which is 
mediated, at least in part, by neutrophils, affects the 
evolution of preneoplastic lesions to cancer in epithelia 
locating distantly from the gut, such as those of the 
mammary glands.
METHODS
Animals
Genetically-inbred FVB-Tg(C3-1-TAg)cJeg/JegJ 
female mice (Jackson Labs, Bar Harbor, ME), were 
housed and handled in Association for Assessment and 
Accreditation of Laboratory Animal Care (AAALAC)-
accredited facilities with diets, experimental methods, 
and housing as specifically approved by the Institutional 
Animal Care and Use Committee. Experimental design 
was to expose mice to Helicobacter hepaticus infection 
by gastric gavage at the age of twelve weeks, and then 
monitor for three weeks until euthanasia using carbon 
dioxide overdose. Control mice of the same age underwent 
gastric gavage with media alone. Subsets of infected 
mice were injected intraperitoneally with anti-Ly-6G 
antibody to deplete neutrophils, or with sham isotype-
matched antibody alone, thrice weekly for 3.5–4 weeks 
starting three days before infection. Each experimental 
group included 5–10 animals per group with one replicate 
experiment with statistically similar outcomes to validate 
results. Mammary tissues were collected upon necropsy 
and then examined histologically.
Experimental infection with Helicobacter 
hepaticus
A total of 51 experimental mice were dosed at 12 
weeks of age with H. hepaticus and then housed separately 
in a bio-containment area within the same animal facility. 
H. hepaticus (strain 3B1, ATCC #51449) [2] was grown 
under microaerobic conditions, prepared, and confirmed 
to be pure as described elsewhere [3]. Experimental mice 
received 0.2 ml of fresh inoculum by gastric gavage every 
other day for a total of three doses. Cecum and stool 
were collected at necropsy 3–4 weeks post-infection and 
analyzed by PCR using H. hepaticus-specific primers to 
confirm bowel colonization.
Systemic depletion of neutrophils
Mice were treated with anti-Ly6G antibody (clone 
1A8; Bio- X-Cell, West Lebanon, NH) at 200 ug per 
mouse intraperitoneally 3X weekly for 3–4 weeks starting 
3 days before infection with H. hepaticus. Treatment with 
antibody continued concurrent with H. hepaticus infection 
for a duration of 3 weeks, with euthanasia occurring at 
age 15 weeks. Treated mice were then compared with 
mice receiving a comparable dose of sham isotype 
antibody alone. Depletion of neutrophils was confirmed 
by undetectably low levels of MPO+ cells in spleens of 
mice treated with anti-Ly-6G antibody compared to sham-
treated controls.
Statistical analyses
The Mann-Whitney U test was used for analyzing 
histomorphometry data. Mammary tumor multiplicity 
was evaluated using the Kruskal-Wallis analysis followed 
by the Dunn’s multiple comparison test. Mammary gland 
lesion staging comparison between groups was done 
with the Chi-square test. Replicate experiments were not 
significantly different. A p-value < 0.05 was statistically 
significant.
Histopathology and immunohistochemistry
For histologic evaluation, formalin-fixed tissues 
were embedded in paraffin, cut at 5 μm, and stained with 
hematoxylin and eosin. Hyperplastic and preneoplastic 
lesions in the mammary gland were staged based 
on previously published consensus criteria [65] as 
previously described [7]. Rabbit polyclonal antibodies 
against Myeloperoxidase (MPO) (ThermoFisher 
Scientific/Lab Vision, Fremont, CA), were used for 
immunohistochemistry. Heat-induced antigen retrieval 
was performed with citrate buffer, pH 6. Rabbit primary 
antibody binding was detected with goat anti-rabbit 
polymer HRP (ZytoChem Plus, Berlin, Germany). Color 
was developed with DAB substrate-chromogen system 
(ThermoFisher Scientific/Lab Vision) and tissues were 
counterstained with hematoxylin.
For quantitative histomorphometry, MPO-positive 
cells were counted in 20 randomly-selected images of 
x20 representative high power fields using the ImageJ 
processing and analysis program (NIH, Bethesda, MD) 
as previously described [7] and results were recorded 
as number of cells per image. The relative percentage 
of abnormal glands belonging to different histological 
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stages of mammary tumorigenesis in H. hepaticus-
infected and non-infected mice was determined in 50 
abnormal mammary duct profiles from each group. For 
that, histological sections from non-tumoral areas of 5 
randomly selected mice per experimental group were used. 
Starting from the upper left corner of each histological 
section and moving towards its lower right, the first 10 
abnormal glands (hyperplastic or with early neoplasia) 
found were staged and the result was recorded.
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